[go: up one dir, main page]

MX2017001540A - Tabletas de rucaparib de dosificacion elevada. - Google Patents

Tabletas de rucaparib de dosificacion elevada.

Info

Publication number
MX2017001540A
MX2017001540A MX2017001540A MX2017001540A MX2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A MX 2017001540 A MX2017001540 A MX 2017001540A
Authority
MX
Mexico
Prior art keywords
rucaparib
high dosage
tablet
dosage strength
strength tablets
Prior art date
Application number
MX2017001540A
Other languages
English (en)
Other versions
MX367260B (es
Inventor
Etter Jeffrey
Original Assignee
Clovis Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology Inc filed Critical Clovis Oncology Inc
Publication of MX2017001540A publication Critical patent/MX2017001540A/es
Publication of MX367260B publication Critical patent/MX367260B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se revela una tableta que incluye una alta dosificación de sal de camsilato de 8-fluoro-2-(4-[(metilamino)metil]fenil)-1,3,4,5-tetra hidro-6H-azepino-[5,4,3-cd]indol-6-ona. La invención es concerniente con tabletas de rucaparib de dosificación elevada. En algunas modalidades, la tableta incluye 45-90% en peso/peso de camsilato de rucaparib. En algunas modalidades, la tableta granulada anhidra incluye 45-90% en peso/peso de camsilato de rucaparib. Una de tales modalidades es una tableta que contiene por lo menos 200 mg de rucaparib. Otra modalidad es una tableta que contiene por lo menos 300 mg de rucaparib.
MX2017001540A 2014-08-22 2015-08-17 Tabletas de rucaparib de dosificación elevada. MX367260B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (2)

Publication Number Publication Date
MX2017001540A true MX2017001540A (es) 2017-05-11
MX367260B MX367260B (es) 2019-08-12

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001540A MX367260B (es) 2014-08-22 2015-08-17 Tabletas de rucaparib de dosificación elevada.

Country Status (22)

Country Link
US (3) US9987285B2 (es)
EP (1) EP3182975B1 (es)
JP (3) JP6574477B2 (es)
KR (2) KR102803917B1 (es)
CN (2) CN106794185A (es)
AU (2) AU2015305696B2 (es)
BR (1) BR112017000865A2 (es)
CA (1) CA2955495C (es)
DK (1) DK3182975T3 (es)
ES (1) ES3048688T3 (es)
FI (1) FI3182975T3 (es)
HR (1) HRP20251484T1 (es)
IL (1) IL249946B (es)
LT (1) LT3182975T (es)
MX (1) MX367260B (es)
NZ (1) NZ728392A (es)
PT (1) PT3182975T (es)
RS (1) RS67356B1 (es)
RU (1) RU2705156C2 (es)
SG (1) SG11201700265VA (es)
SI (1) SI3182975T1 (es)
WO (1) WO2016028689A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220136460A (ko) 2014-02-05 2022-10-07 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
KR20190110579A (ko) 2017-01-24 2019-09-30 아시아 케미컬 인더스트리스 리미티드 루카파립 및 루카파립 염의 고체상 형태
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
KR20200058496A (ko) * 2017-09-26 2020-05-27 테사로, 인코포레이티드 니라파립 제제
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
PH12022550039A1 (en) 2019-07-10 2023-06-26 Cybrexa 3 Inc Peptide conjugates of cytotoxins as therapeutics
PH12022552854A1 (en) 2020-04-28 2023-03-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.
US12350259B2 (en) 2021-09-27 2025-07-08 Allergan Pharmaceuticals International Limited Methods of treating migraine
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
BRPI0412899B1 (pt) 2003-07-25 2021-10-05 Cancer Research Technology Limited Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático
CN101027306B (zh) 2004-09-22 2010-10-27 辉瑞有限公司 聚(adp-核糖)聚合酶抑制剂的制备方法
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
RS59494B1 (sr) * 2010-02-12 2019-12-31 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona
RS56673B1 (sr) * 2012-04-05 2018-03-30 Vertex Pharma Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마＆ 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제

Also Published As

Publication number Publication date
FI3182975T3 (fi) 2025-11-13
KR102803917B1 (ko) 2025-05-07
IL249946B (en) 2020-05-31
JP2021038242A (ja) 2021-03-11
SI3182975T1 (sl) 2025-12-31
CA2955495C (en) 2023-09-19
US20160051561A1 (en) 2016-02-25
EP3182975B1 (en) 2025-10-01
KR20170043597A (ko) 2017-04-21
AU2019272064A1 (en) 2019-12-19
US9987285B2 (en) 2018-06-05
EP3182975A4 (en) 2018-04-18
BR112017000865A2 (pt) 2017-12-05
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05
CA2955495A1 (en) 2016-02-25
JP2020002149A (ja) 2020-01-09
SG11201700265VA (en) 2017-02-27
JP6574477B2 (ja) 2019-09-11
PT3182975T (pt) 2025-10-28
WO2016028689A1 (en) 2016-02-25
IL249946A0 (en) 2017-03-30
ES3048688T3 (en) 2025-12-11
MX367260B (es) 2019-08-12
JP7127101B2 (ja) 2022-08-29
AU2015305696B2 (en) 2019-08-29
AU2015305696A1 (en) 2017-02-02
DK3182975T3 (da) 2025-10-20
US20190099430A1 (en) 2019-04-04
HRP20251484T1 (hr) 2026-01-02
KR20230097211A (ko) 2023-06-30
NZ728392A (en) 2023-06-30
EP3182975A1 (en) 2017-06-28
CN106794185A (zh) 2017-05-31
US20180200260A1 (en) 2018-07-19
CN113209033A (zh) 2021-08-06
US10130636B2 (en) 2018-11-20
RS67356B1 (sr) 2025-11-28
JP2017525712A (ja) 2017-09-07
RU2017109139A (ru) 2018-09-24
AU2019272064B2 (en) 2021-11-18
RU2017109139A3 (es) 2019-03-06
LT3182975T (lt) 2025-11-25

Similar Documents

Publication Publication Date Title
MX2017001540A (es) Tabletas de rucaparib de dosificacion elevada.
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
SI3152212T1 (sl) Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
SI3077397T1 (sl) 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
SI3227297T1 (sl) 4,6-substituirani-pirazolo(1,5-A)pirazini kot inhibitorji Janus kinaze
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
GEAP201814408A (en) Quinolizinone derivatives as pi3k inhibitors
SI3596080T1 (sl) Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati
PL3102187T3 (pl) Stabilne kompozycje farmaceutyczne zawierające sitagliptynę w postaci tabletek o natychmiastowym uwalnianiu
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
TW201613586A (en) Pharmaceutical dosage forms
HK1236034A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
HK1236035A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Legal Events

Date Code Title Description
FG Grant or registration